Cargando…

Current therapy in children and adolescents with von Willebrand disease

Abstract The article represents a review of recent data about the therapy of von Willebrand disease in children and adolescents (hereditary as well as acquired forms of the disease). The treatment of bleeding events in these patients, the indications in different subtypes, and the future lines of re...

Descripción completa

Detalles Bibliográficos
Autores principales: Buga-Corbu, I, Arion, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Carol Davila University Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4197504/
https://www.ncbi.nlm.nih.gov/pubmed/25408737
_version_ 1782339638434725888
author Buga-Corbu, I
Arion, C
author_facet Buga-Corbu, I
Arion, C
author_sort Buga-Corbu, I
collection PubMed
description Abstract The article represents a review of recent data about the therapy of von Willebrand disease in children and adolescents (hereditary as well as acquired forms of the disease). The treatment of bleeding events in these patients, the indications in different subtypes, and the future lines of research are mentioned. Abbreviations: Ag VWF = von Willebrand antigen, VWD = von Willebrand disease, DDAVP = arginine-vasopressin, EACA = epsilon aminocaproic acid, VWF = von Willebrand factor, VIIc F = the VIIth factor of coagulation, VIIIc F = the VIIIth factor of coagulation, IgG = immunoglobulin G, T/2 = half-time, WVF – Rco = the ristocetin cofactor.
format Online
Article
Text
id pubmed-4197504
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Carol Davila University Press
record_format MEDLINE/PubMed
spelling pubmed-41975042014-11-18 Current therapy in children and adolescents with von Willebrand disease Buga-Corbu, I Arion, C J Med Life Case Presentation Abstract The article represents a review of recent data about the therapy of von Willebrand disease in children and adolescents (hereditary as well as acquired forms of the disease). The treatment of bleeding events in these patients, the indications in different subtypes, and the future lines of research are mentioned. Abbreviations: Ag VWF = von Willebrand antigen, VWD = von Willebrand disease, DDAVP = arginine-vasopressin, EACA = epsilon aminocaproic acid, VWF = von Willebrand factor, VIIc F = the VIIth factor of coagulation, VIIIc F = the VIIIth factor of coagulation, IgG = immunoglobulin G, T/2 = half-time, WVF – Rco = the ristocetin cofactor. Carol Davila University Press 2014-06-15 2014-06-25 /pmc/articles/PMC4197504/ /pubmed/25408737 Text en ©Carol Davila University Press http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Presentation
Buga-Corbu, I
Arion, C
Current therapy in children and adolescents with von Willebrand disease
title Current therapy in children and adolescents with von Willebrand disease
title_full Current therapy in children and adolescents with von Willebrand disease
title_fullStr Current therapy in children and adolescents with von Willebrand disease
title_full_unstemmed Current therapy in children and adolescents with von Willebrand disease
title_short Current therapy in children and adolescents with von Willebrand disease
title_sort current therapy in children and adolescents with von willebrand disease
topic Case Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4197504/
https://www.ncbi.nlm.nih.gov/pubmed/25408737
work_keys_str_mv AT bugacorbui currenttherapyinchildrenandadolescentswithvonwillebranddisease
AT arionc currenttherapyinchildrenandadolescentswithvonwillebranddisease